# Laboratorios Silanes S.A. de C.V. clinical trials: 45 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 45 trials with Laboratorios Silanes S.A. de C.V. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Laboratorios Silanes S.A. de C.V.: 45 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/laboratorios-silanes-s-a-de-c-v

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 45
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 45, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07901894 | Study to Evaluate the Efficacy and Safety of Dexketoprofen / Butylscopolamine vs Dexketoprofen in Treatment of Primary Dysmenorrhea | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Primary Dysmenorrhea | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901894) |
| March 6, 2026 | NCT07454369 | Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination | Laboratorios Silanes S.A. de C.V. | Phase 1 | Completed | Healthy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454369) |
| March 2, 2026 | NCT07444164 | Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination. | Laboratorios Silanes S.A. de C.V. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444164) |
| January 8, 2026 | NCT07328022 | Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Bursitis, Tendinitis, Synovitis | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328022) |
| April 8, 2025 | NCT06916884 | Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Allergic Rhinitis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06916884) |
| March 7, 2025 | NCT06863701 | Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis | Laboratorios Silanes S.A. de C.V. | Phase 3 | Recruiting | Gout Arthritis, Gout Attack | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06863701) |
| March 7, 2025 | NCT06863662 | Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Acute Low-back Pain, Muscle Spasm; Back Pain | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06863662) |
| March 7, 2025 | NCT06863636 | Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Joint Pain, Knee Osteoarthritis, Hip Osteoarthritis | 231 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06863636) |
| August 1, 2024 | NCT06531707 | Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Common Cold | 177 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06531707) |
| July 24, 2024 | NCT06517823 | Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Acute Low-back Pain | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06517823) |
| July 23, 2024 | NCT06516094 | Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Chronic Low-back Pain | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06516094) |
| September 8, 2022 | NCT05533073 | Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in Combination | Laboratorios Silanes S.A. de C.V. | Phase 1 | Completed | Healthy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05533073) |
| June 23, 2022 | NCT05428306 | Pharmacokinetic Interaction Between Ibuprofen and Acetaminophen, Tablets Administered Individually or in Combination | Laboratorios Silanes S.A. de C.V. | Phase 1 | Completed | Healthy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05428306) |
| June 23, 2022 | NCT05428293 | Pharmacokinetic Interaction Between Ibuprofen and Acetaminophen Oral Suspension | Laboratorios Silanes S.A. de C.V. | Phase 1 | Completed | Healthy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05428293) |
| May 25, 2022 | NCT05389150 | Non-interaction Study Between Pregabalin and Tramadol, Administered Individually or Combination, in Healthy Subjects | Laboratorios Silanes S.A. de C.V. | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05389150) |
| April 12, 2022 | NCT05324059 | Efficacy and Safety of Pregabalin/Tramadol Combination Versus Pregabalin in Acute Pain of Neuropathic Origin | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Neuropathic Pain | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05324059) |
| November 3, 2021 | NCT05105139 | Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp | Laboratorios Silanes S.A. de C.V. | Observational | Completed | Seborrheic Dermatitis, Psoriasis of Scalp | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05105139) |
| October 22, 2021 | NCT05090449 | Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions | Laboratorios Silanes S.A. de C.V. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05090449) |
| August 30, 2021 | NCT05027126 | Comparison of Bioavailability of Dexketoprofen-Vit B vs Dexketoprofen, in Healthy Subjects, Under Fasting Conditions | Laboratorios Silanes S.A. de C.V. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05027126) |
| August 12, 2021 | NCT05001555 | Efficacy and Safety of Dexketoprofen/Vitamin B Vs Dexketoprofen for Post-traumatic Cervical Sprain Grade I-II | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Acute Low Back Pain | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05001555) |
| July 20, 2021 | NCT04968158 | Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back Pain | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Acute Low Back Pain | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04968158) |
| June 29, 2021 | NCT04943692 | Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes | Laboratorios Silanes S.A. de C.V. | Phase 3 | Suspended | Type 2 Diabetes | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04943692) |
| June 15, 2021 | NCT04927299 | Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Essential Arterial Hypertension | 163 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04927299) |
| June 8, 2021 | NCT04916899 | Safety of doTBal® in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program | Laboratorios Silanes S.A. de C.V. | Observational | Completed | Tuberculosis | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04916899) |
| May 20, 2021 | NCT04895059 | Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components | Laboratorios Silanes S.A. de C.V. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04895059) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 3 | 18 |
| Phase 4 | 2 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 37 |
| Unknown | 4 |
| Suspended | 2 |
| Withdrawn | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 9 |
| Diabetes Mellitus | 5 |
| Acute Pain | 4 |
| Pain | 3 |
| Dyslipidemias | 3 |
| Obesity | 3 |
| Back Pain | 2 |
| Severe Acute Respiratory Syndrome | 2 |
| Spasm | 1 |
| Hypertriglyceridemia | 1 |
| Neuralgia | 1 |
| Tuberculosis | 1 |
| Pediatric Obesity | 1 |
| Rhinitis, Allergic | 1 |
| Rhinitis | 1 |
| Hypersensitivity | 1 |
| Metabolic Syndrome | 1 |
| Arthralgia | 1 |
| Osteoarthritis, Knee | 1 |
| Osteoarthritis, Hip | 1 |
| Common Cold | 1 |
| Influenza, Human | 1 |
| Hypertension | 1 |
| Arthritis, Gouty | 1 |
| Dermatitis, Seborrheic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Cancer treatment centers in the United States](https://specstream.ai/data/businesses/cancer-treatment-centers/united-states)
- [Speech training companies in the United States](https://specstream.ai/data/businesses/speech-training-companies/united-states)
- [Jamaican restaurants in the United States](https://specstream.ai/data/businesses/jamaican-restaurants/united-states)
- [Chiropractic clinics in the United States](https://specstream.ai/data/businesses/chiropractic-clinics/united-states)
- [Taiwanese restaurants in the United States](https://specstream.ai/data/businesses/taiwanese-restaurants/united-states)
